reports
- Wedbush Research
DPZ DOMINO'S PIZZA INC.
KMX CARMAX INC.
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
XNCR XENCOR INC.
WDC WESTERN DIGITAL CORPORATION
WAL WESTERN ALLIANCE BANCORP
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RWT REDWOOD TRUST INC.
PEGA PEGASYSTEMS INC.
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NRZ NEW RESIDENTIAL INVESTMENT CORP.
MFA MFA FINANCIAL INC.
KURA KURA ONCOLOGY INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FTNT FORTINET INC.
CYBR CYBERARK SOFTWARE LTD.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
ABR ARBOR REALTY TRUST INC.
WD WALKER & DUNLOP INC.
CMA COMERICA INCORPORATED
CVNA CARVANA CO. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
RCUS ARCUS BIOSCIENCES
ZS ZSCALER INC.
RC READY CAPITAL CORPORATION
COOP MR. COOPER GROUP INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SWTX SPRINGWORKS THERAPEUTICS
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PFSI PENNYMAC FINANCIAL SERVICES INC.
RVMD REVOLUTION MEDICINES
ORIC ORIC PHARMACEUTICALS
RKT ROCKET COMPANIES
IMNM IMMUNOME
WOOF PETCO HEALTH AND WELLNESS
DAWN DAY ONE BIOPHARMACEUTICALS INC
GHLD GUILD HOLDINGS
TNGX TANGO THERAPEUTICS
UWMC INC
TYRA UWM HLDGS CORP
EWTX TYRA BIOSCIENCES INC
RBRK EDGEWISE THERAPEUTICS INC
RUBRIK INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Sym...
ORIC® Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present a poster at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held October 23-25, 2024, in Barcelona, Spain. Poster presentation details: Title:ORIC-114, a hi...
Clene to Present at Upcoming October Conferences
Clene to Present at Upcoming October Conferences SALT LAKE CITY, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that it will participate in the following investor conferences in October. 2024 Maxim Healthcare Virtual SummitDate: October 15-17, ...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 1, 2024 (the “Grant Date”), ORIC granted a total of 92,400 non-qualified stock options and 16,300 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2024. These inducement grants were...
Clene Announces Closing of $7.3 Million Registered Direct Offering and...
Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility Investment led by healthcare-focused institutional investor with participation from SymBiosis; founding investor Kensington Capital Holdings; Clene’s Chairman of the Board of Directors, Chief Executive Officer and Chief Scientific Officer and Founder; along with support from several other previously existing shareholders$7.3 million registered direct offering and concurrent private placements priced at market under Nasdaq rulesAmended debt facility with Avenue ...
Team, Inc. Announces Amendment and Maturity Extension of Its ABL Credi...
Team, Inc. Announces Amendment and Maturity Extension of Its ABL Credit Facility Amendment Provides Additional Liquidity and Improved Pricing SUGAR LAND, Texas, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering clients access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, announced today that it has executed an amendment to its existing ABL credit facility, which consists of a $130 million revolving credit facility (th...
Clene Announces $7.3 Million Registered Direct Offering and Concurrent...
Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules SALT LAKE CITY, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly-owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that on September 30, 2024 it entered into a securities...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Wedbush Research
Farmers & Merchants Bancorp (FMCB) Authorizes a New $55 Million Share ...
Farmers & Merchants Bancorp (FMCB) Authorizes a New $55 Million Share Repurchase Program LODI, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Farmers & Merchants Bancorp (OTCQX: FMCB) (the “Company” or “FMCB”), the parent company of Farmers & Merchants Bank of Central California (the “Bank” or “F&M Bank”), announced that, effective immediately, the Company has authorized a new $55.0 million share repurchase program through December 31, 2026. The existing $25.0 million share repurchase program approved in November 2023 has been terminated. The Company has utilized a share repurchase program f...
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss ...
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data SALT LAKE CITY, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), announced today that it will meet in-person with the U.S. Foo...
- Wedbush Research
WING WINGSTOP INC.
MRSN MERSANA THERAPEUTICS
ZG ZILLOW GROUP INC. CLASS A
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
U UNITY SOFTWARE
RKT ROCKET COMPANIES
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
FHTX FOGHORN THERAPEUTICS
TCRX TSCAN THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
- David Nierengarten
- Dennis Pak
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
MRSN MERSANA THERAPEUTICS
RCUS ARCUS BIOSCIENCES
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
IMNM IMMUNOME
NUVB NUVATION BIO INC (A)
CGEM CULLINAN ONCOLOGY INC
FHTX FOGHORN THERAPEUTICS
TCRX TSCAN THERAPEUTICS INC
JANX JANUX THERAPEUTICS INC
NUVL NUVALENT INC
- Wedbush Research
TRIP TRIPADVISOR INC.
PRGS PROGRESS SOFTWARE CORPORATION
NVCR NOVOCURE LTD.
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
DRI DARDEN RESTAURANTS INC.
MRSN MERSANA THERAPEUTICS
VTR VENTAS INC.
SE SEA ADS
AMZN AMAZON.COM INC.
AAPL APPLE INC.
BKNG BOOKING HOLDINGS INC.
EPRT ESSENTIAL PROPERTIES REALTY TRUST
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
RVMD REVOLUTION MEDICINES
BDTX BLACK DIAMOND THERAPEUTICS
ORIC ORIC PHARMACEUTICALS
ZNTL ZENTALIS PHARMACEUTICALS
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
CGEM CULLINAN ONCOLOGY INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
FHTX FOGHORN THERAPEUTICS
TCRX TSCAN THERAPEUTICS INC
NUVL NUVALENT INC
ANRO ALTO NEUROSCIENCE INC
BNL BROADSTONE NET LEASE INC
RBRK RUBRIK INC
- David Nierengarten
- Dennis Pak
- Martin Fan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Ru...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 3, 2024 (the “Grant Date”), ORIC granted a total of 173,200 non-qualified stock options and 28,900 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2024. These inducement grants we...
Clene to Present at the H.C. Wainwright 26th Annual Global Investment ...
Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference an...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in September: 2024 Wells Fargo Healthcare Conference – Participating in a fireside chat on Thursday, September 5, 2024, at 8:00 a.m. ET Baird 2024 Global Healthcare Conference (Available to conferenc...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.